Premium
Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria
Author(s) -
GiménezArnau A. M.,
Toubi E.,
Marsland A. M.,
Maurer M.
Publication year - 2016
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.13697
Subject(s) - omalizumab , medicine , chronic urticaria , antihistamine , clinical practice , intensive care medicine , clinical trial , dermatology , medline , family medicine , immunoglobulin e , immunology , political science , antibody , law
Abstract This supplement reports proceedings of the second international Global Urticaria Forum, which was held in Berlin, Germany in November 2015. Omalizumab is approved for the treatment of chronic spontaneous urticaria ( CSU ) in adult and adolescent (12 years and above) patients with inadequate response to/who remain symptomatic despite H 1 ‐antihistamine treatment, and has demonstrated good efficacy and safety in the clinical trial setting. Real‐life clinical experience with omalizumab can be explored to address important practical questions relating to its use in CSU patients. Some experts have proposed that a consensus algorithm, covering various aspects to consider when using omalizumab in real‐life clinical practice for the management of CSU , could answer many of these questions.